Aclaris Therapeutics (ACRS) - Marktkap: $43 M - Reboundplay (Seite 19)
eröffnet am 13.09.19 08:31:34 von
neuester Beitrag 01.02.24 00:59:35 von
neuester Beitrag 01.02.24 00:59:35 von
Beiträge: 2.342
ID: 1.311.638
ID: 1.311.638
Aufrufe heute: 0
Gesamt: 287.953
Gesamt: 287.953
Aktive User: 0
ISIN: US00461U1051 · WKN: A1412H · Symbol: 8AT
1,2590
EUR
+3,45 %
+0,0420 EUR
Letzter Kurs 03.05.24 Tradegate
Neuigkeiten
30.04.24 · globenewswire  |
27.02.24 · globenewswire |
16.01.24 · globenewswire |
10.01.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 13,110 | +38,44 | |
| 6,5000 | +27,45 | |
| 1,2100 | +21,00 | |
| 48,25 | +19,94 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,2600 | -14,25 | |
| 3,8500 | -14,45 | |
| 1,0011 | -15,88 | |
| 36,70 | -22,87 | |
| 2,5600 | -70,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights
●
Projected Cash Runway into the First Quarter of 2022
●
Borrowed $11 Million from Term Loan Facility
Wayne, PA – May 7, 2020 (GLOBE NEWSWIRE) –
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced its financial results for the first quarter of 2020 and provided research and development (R&D) and business highlights.
“In the first quarter, we borrowed $11 million from Silicon Valley Bank enabling us to extend our cash runway, and started enrolling subjects with moderate-to-severe rheumatoid arthritis in our Phase 2a trial of ATI-450. As a result of the COVID-19 pandemic and as a precautionary measure, we temporarily paused subject enrollment in this trial. At this time, we have decided to resume enrollment at one clinical trial site. We will continue to monitor the COVID-19 pandemic and engage additional clinical trial sites, as appropriate, based on our assessment of the impact on our trial. I’m proud of our team’s focus, dedication and resilience while navigating through the unique challenges that the COVID-19 pandemic has created,” said Dr. Neal Walker, President and CEO of Aclaris.
R&D Highlights:
The global outbreak of COVID-19 continues to rapidly evolve and has caused and may continue to cause Aclaris to experience disruptions that could impact the timing of its regulatory and research and development activities listed below.
● ATI-450:
o ATI-450 is an investigational oral small molecule MK2 inhibitor.
o ATI-450-RA-201: A Phase 2a trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 in subjects with moderate-to-severe rheumatoid arthritis.
◾ Aclaris started subject enrollment in the first quarter of 2020. Due to the COVID-19 pandemic, Aclaris temporarily paused enrollment of subjects in the trial. At this time, Aclaris has decided to resume enrolling subjects at one clinical trial site. The initiation of additional clinical trial sites will be determined on an ongoing basis as the COVID-19 pandemic evolves.
https://last10k.com/sec-filings/acrs/0001558370-20-009814.ht…
●
Projected Cash Runway into the First Quarter of 2022
●
Borrowed $11 Million from Term Loan Facility
Wayne, PA – May 7, 2020 (GLOBE NEWSWIRE) –
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced its financial results for the first quarter of 2020 and provided research and development (R&D) and business highlights.
“In the first quarter, we borrowed $11 million from Silicon Valley Bank enabling us to extend our cash runway, and started enrolling subjects with moderate-to-severe rheumatoid arthritis in our Phase 2a trial of ATI-450. As a result of the COVID-19 pandemic and as a precautionary measure, we temporarily paused subject enrollment in this trial. At this time, we have decided to resume enrollment at one clinical trial site. We will continue to monitor the COVID-19 pandemic and engage additional clinical trial sites, as appropriate, based on our assessment of the impact on our trial. I’m proud of our team’s focus, dedication and resilience while navigating through the unique challenges that the COVID-19 pandemic has created,” said Dr. Neal Walker, President and CEO of Aclaris.
R&D Highlights:
The global outbreak of COVID-19 continues to rapidly evolve and has caused and may continue to cause Aclaris to experience disruptions that could impact the timing of its regulatory and research and development activities listed below.
● ATI-450:
o ATI-450 is an investigational oral small molecule MK2 inhibitor.
o ATI-450-RA-201: A Phase 2a trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 in subjects with moderate-to-severe rheumatoid arthritis.
◾ Aclaris started subject enrollment in the first quarter of 2020. Due to the COVID-19 pandemic, Aclaris temporarily paused enrollment of subjects in the trial. At this time, Aclaris has decided to resume enrolling subjects at one clinical trial site. The initiation of additional clinical trial sites will be determined on an ongoing basis as the COVID-19 pandemic evolves.
https://last10k.com/sec-filings/acrs/0001558370-20-009814.ht…
$ACRS
Great news! “FIRST SUBJECT DOSED IN PHASE 2a TRIAL FOR CYTOKINE RELEASE SYNDROME IN HOSPITALIZED PATIENTS WITH COVID-19.....”. This is a 14 day trial....data soon....oral drug will be positive.....ATI-450 attacks several cytokine storm inititiators not just one or two like most drugs being tested. Seekingalpha update coming up......
Stocktwits
Great news! “FIRST SUBJECT DOSED IN PHASE 2a TRIAL FOR CYTOKINE RELEASE SYNDROME IN HOSPITALIZED PATIENTS WITH COVID-19.....”. This is a 14 day trial....data soon....oral drug will be positive.....ATI-450 attacks several cytokine storm inititiators not just one or two like most drugs being tested. Seekingalpha update coming up......
Stocktwits
Antwort auf Beitrag Nr.: 64.675.867 von liquidx am 06.08.20 22:44:51weiss jemand warum eigentlich genau, hielt sich doch die anderen Wochen ganz gut und jetzt.
Na toll....
der Kurs is schon bei 1,80 USD AH.... sieht nicht gut aus wohl
der Kurs is schon bei 1,80 USD AH.... sieht nicht gut aus wohl
Antwort auf Beitrag Nr.: 64.648.414 von sleepy_d am 05.08.20 07:37:03Finde ich auch. Bin noch dabei. Kommen morgen nicht die Zahlen?
Trading Spotlight
Die Aktie hält sich erstaunlich gut. Habe eigentlich erwartet, dass es nach dem Ausschlag direkt wieder runter rauscht.
Ich bleibe vorsichtig optimistisch.
Ich bleibe vorsichtig optimistisch.
Es ist doch wirklich so, dass man echt jeden größeren Anstieg direkt nutzen sollte, um Gewinne zu sichern... ACRS war wieder mal der Beweis dafür, dass es ohne Grund steigt und dann massiv fällt.
Schade, schade....
Schade, schade....
Hm?,
2,26 heute bei mir
na ja, bin jetzt raus...hab mit Lipocine,achieve life, Happiness, Capricor , Xeris nach ein paar Eisen im Börsenfeuer.........
Good luck
M.
2,26 heute bei mir
na ja, bin jetzt raus...hab mit Lipocine,achieve life, Happiness, Capricor , Xeris nach ein paar Eisen im Börsenfeuer.........
Good luck
M.
Antwort auf Beitrag Nr.: 64.525.302 von manffreddoo am 23.07.20 21:57:53https://de.advfn.com/borse/NASDAQ/ACRS/kurs
Mir werden 2,39$ angezeigt?!🤔
Mir werden 2,39$ angezeigt?!🤔
Antwort auf Beitrag Nr.: 64.507.254 von Potatoehead am 22.07.20 17:37:45 hi,
durch!
...und ich bin drauss........
Good luck
M.
durch!
...und ich bin drauss........
Good luck
M.
Durchsuchen
